DG
INDP icon

Delek Group’s Indaptus Therapeutics INDP Stock Holding History

Delek Group’s Portfolio INDP Stock Details INDP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		$137K Buy
14
+5
+56% +$63.1K 0.01% 215
2019
Q1 		$154K Buy
+9
New +$158K 0.01% 203

Other funds holding INDP

MIH
Meitav Investment House Bene-Beraq, Israel $14.9B AUM 46.8% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $143M AUM 102.52% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 57.61% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return

Delek Group's INDP Position: Q2 2019 in Review

Delek Group increased its Indaptus Therapeutics (INDP) stake by 56% in Q2 2019, buying an estimated $63.1K and bringing the position to 14 shares worth $137K. The position accounts for 0.01% of the portfolio, ranked #215.

Delek Group first reported a position in INDP in Q1 2019 and has held it in 2 quarters since. The position peaked at $154K in Q1 2019. 47 funds tracked by Wall St. Rank hold INDP as of Q2 2019.

  • Delek Group held 14 shares of Indaptus Therapeutics worth $137K as of Q2 2019.
  • Delek Group bought 5 Indaptus Therapeutics shares in Q2 2019, an estimated $63.1K.
  • Indaptus Therapeutics made up 0.01% of Delek Group's portfolio in Q2 2019, its #215 holding.
  • Delek Group first reported a position in Indaptus Therapeutics in Q1 2019 and has held it in 2 quarters since.
  • Delek Group's Indaptus Therapeutics position peaked at $154K in Q1 2019.
  • 47 funds tracked by Wall St. Rank held Indaptus Therapeutics as of Q2 2019.

Based on Delek Group's 13F filing for Q2 2019, filed 8 Aug 2019.